Navigation Links
Imaging agents predict breast cancer response to endocrine therapy
Date:7/2/2012

Reston, Va. (July 2, 2012) Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage. Estrogen receptor-α (ERα) status is an important factor in determining the most appropriate treatment for breast cancer patients, especially for those who are ERα+ and likely to respond well to hormone-based, or endocrine, therapies.

Prominent professor and research chemist Michael J. Welch, PhD, who passed away in May, was a contributing author for this research. "Throughout his career, Dr. Welch specialized in the synthesis of new radiolabeled compounds for medical imaging, with a special emphasis on the growing numbers of applications in PET," said Dominique Delbeke, MD, PhD, editor of The Journal of Nuclear Medicine. Noted for his ability to see beyond the immediate aspects of basic work to potential future applications, Welch was both a prime mover and an integral part in the development of PET as it transitioned from a compelling investigative idea to widespread clinical acceptance. "Many of his discoveries and research will live on well into the future," said Delbeke.

The study, "Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer" was an example of his unique approach to research.

"Positron emission tomography, or PET, has typically been used to identify the target for endocrine therapy in breast cancer by demonstrating that ER is present in tumors using F-18-fluoroestradiol (FES)-PET, or by monitoring for hormone-induced changes in tumor metabolism'metabolic flare' with F-18-fluorodeoxyglucose (FDG)-PET once therapy has begun. What is novel about our study is that we chose to image progesterone receptor levels to see how the estrogen signaling pathway is functioning in response to endocrine therapy," said Amy Fowler, MD, PhD, lead author of the study.

In the study, mice with mammary cell lines (SSM1, SSM2 and SSM3) derived from STAT1-deficient mammary tumorswhich are ERα+/PR+ and similar to the majority of human breast cancerswere imaged. Small-animal PET/computed tomography (CT) was performed using F-18-FES to image estrogen receptor status, F-18-fluoro furanyl norprogesterone (F-18-FFNP) for progesterone receptor status, and FDG for glucose uptake.

Initial imaging of the cell lines showed that SSM3 tumors displayed the greatest F-18-FES and F-18-FFNP uptake, and therefore, the SSM3 cell line was used to test the response to estradiol, an ER agonist, and fulvestrant, a pure ER antagonist. Upon treatment with estradiol, it was determined that PR expression is estrogen-inducible and indicative of ERα signaling in the SSM3 tumors. Mice treated with fulvestrant showed early decreases in F-18-FFNP uptake after initiation of therapy, prior to measurable growth inhibition. SSM2 tumors, which were not growth-inhibited by fulvestrant despite also being ERα+/PR+, showed no change in F-18-FFNP uptake after initiation of therapy. These data support the potential use of PR imaging with F-18-FFNP PET of patients with ERα+ breast cancer at baseline and shortly after initiation of endocrine therapy to distinguish between responders and nonresponders, and thus help facilitate the selection of therapies most appropriate for individual patients.

"An important goal of molecular imaging in cancer research is to noninvasively predict early responses to therapies in order to guide further management," noted Fowler. "Our work using a preclinical model of breast cancer helps support the notion that molecular imaging can achieve this goal by testing whether the target utilized for a specific therapy is not only present but also functional."

An estimated one in eight women will develop breast cancer in her lifetime. According to the American Cancer Society, an estimated 280,000 new cases of breast cancer were diagnosed among women in 2011, and nearly 40,000 died from the disease.


'/>"/>

Contact: Susan Martonik
smartonik@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Mount Sinai is first in New York state to perform new Alzheimers imaging test in clinical setting
2. Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
3. Fox Chase researchers find no disparities in imaging before breast cancer surgery
4. Study examines necessity of additional imaging in PET/CT oncologic reports
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
7. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
8. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
9. Pig stomach mucins are effective as anti-viral agents for consumer products
10. Greater L.A. Heating Up, Climate Experts Predict
11. Blood test for pregnant women could predict risk of having dangerously small babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... AR (PRWEB) , ... October 13, 2017 , ... ... with locations throughout Arkansas that offers insurance and financial preparation services, is providing ... the Rock City Rescue organization. , Rock City Rescue is a locally recognized ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
Breaking Medicine Technology: